ATR 101

Drug Profile

ATR 101

Alternative Names: ATR-101

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer Millendo Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Acetyl CoA C-acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia; Cushing syndrome
  • Phase I Adrenocortical carcinoma

Most Recent Events

  • 08 Nov 2017 ATR 101 receives Orphan Drug status for Congenital adrenal hyperplasia in USA
  • 08 Nov 2017 Positive top-line safety and efficacy data from a phase II trial in Congenital adrenal hyperplasia released by Millendo Therapeutics
  • 08 Nov 2017 Millendo Therapeutics completes a phase II trial in Congenital adrenal hyperplasia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top